1. Clinical Overview
A fixed-dose combination (FDC) of a non-selective beta-adrenergic receptor antagonist (Timolol) and a selective alpha-2 adrenergic receptor agonist (Brimonidine). This combination is primarily used in the management of open-angle glaucoma and ocular hypertension. It provides a synergistic intraocular pressure (IOP) lowering effect through complementary mechanisms, often allowing for reduced dosing frequency and improved patient adherence compared to monotherapy.
| Onset | Duration | Bioavailability |
|---|---|---|
| Timolol: 30 minutes; Brimonidine: 1 hour. Combined effect on IOP reduction begins within 1-2 hours. | Timolol: 12-24 hours; Brimonidine: 8-12 hours. The combination provides effective IOP control for up to 12 hours. | Ocular bioavailability is low (<5% for each drug) due to systemic absorption via nasolacrimal duct. Systemic bioavailability after ocular administration: Timolol ~80%, Brimonidine ~32%. |
2. Mechanism of Action
The combination reduces intraocular pressure (IOP) through two distinct and complementary pathways. Timolol, a non-selective beta-adrenergic antagonist, reduces aqueous humor production by blocking beta-2 receptors on the ciliary epithelium. Brimonidine, a selective alpha-2 adrenergic agonist, reduces aqueous humor production and increases uveoscleral outflow. The net effect is a greater and more sustained reduction in IOP than either agent alone.
3. Indications & Uses
- Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma
- Ocular hypertension
4. Dosage & Administration
Adult Dosage: One drop instilled into the affected eye(s) twice daily (approximately every 12 hours).
Administration: 1. Wash hands. 2. Tilt head back. 3. Gently pull lower eyelid to form a pouch. 4. Instill one drop. 5. Close eyes gently for 1-2 minutes, applying light pressure with finger at the inner corner of the eye (nasolacrimal occlusion) to minimize systemic absorption. 6. Wait at least 5 minutes before instilling any other topical ophthalmic medication. Do not touch dropper tip to eye or any surface.
5. Side Effects
Common side effects may include:
- Ocular hyperemia (redness)
- Burning or stinging on instillation
- Foreign body sensation
- Itching
- Blurred vision (transient)
- Bitter taste in mouth (due to nasolacrimal drainage)
- Headache
- Dry mouth (with Brimonidine)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Oral Beta-Blockers (e.g., Propranolol, Atenolol) | Additive systemic beta-blockade; increased risk of bradycardia, AV block, heart failure. | Major |
| Calcium Channel Blockers (e.g., Verapamil, Diltiazem) | Potentiates cardiovascular depression, severe bradycardia, and heart block. | Major |
| Digoxin | Additive bradycardia. | Moderate |
| Clonidine (oral or patch) | Additive alpha-2 agonist effects; rebound hypertension if discontinued concurrently. | Moderate |
| Tricyclic Antidepressants (e.g., Amitriptyline) | May antagonize the IOP-lowering effect of Timolol. | Moderate |
| Insulin, Oral Hypoglycemics | Timolol may mask tachycardia as a sign of hypoglycemia and may impair glucose recovery. | Moderate |
| CYP2D6 Inhibitors (e.g., Fluoxetine, Quinidine) | May increase systemic levels of both Timolol and Brimonidine. | Moderate |
| Other CNS Depressants (Alcohol, Benzodiazepines, Opioids) | May potentiate drowsiness and fatigue caused by Brimonidine. | Moderate |
7. Patient Counselling
- DO instill exactly as prescribed, usually twice daily.
- DO practice nasolacrimal occlusion (pressing inner corner of eye) for 1-2 minutes after instillation.
- DO wait at least 5 minutes before using other eye drops.
- DO keep the bottle tip clean and do not let it touch your eye.
- DO report any eye pain, redness, itching, or vision changes immediately.
- DONT stop the medication without consulting your doctor, even if you feel fine.
- DONT wear soft contact lenses while using this medication; preservative (benzalkonium chloride) can be absorbed.
- DONT drive immediately after instillation if vision is blurred.
8. Toxicology & Storage
Overdose: Ocular Overdose: Flushing, lacrimation, severe ocular irritation. Systemic Overdose (from accidental ingestion or excessive ocular absorption): Bradycardia, hypotension, bronchospasm, respiratory depression, dizziness, syncope, hypothermia (in infants), lethargy, coma.
Storage: Store at room temperature (15°C to 25°C). Protect from light. Keep the bottle tightly closed when not in use. Do not freeze. Keep out of reach and sight of children. Discard the bottle 28 days after first opening to prevent contamination. Do not use if the solution is discolored or contains particles.